Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001181431-13-040378)

Filing Details

Accession Number:: 0001181431-13-040378
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-07-17 17:47:36
Reporting Period:: 2013-07-15

Filing Date:: 2013-07-17
Accepted Time:: 2013-07-17 17:47:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1274644	Ocera Therapeutics Inc.	OCRX	Pharmaceutical Preparations (2834)	631192270

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1211465	P L Vi Partners Venture Sofinnova	2800 Sand Hill Road, Suite 150 Menlo Park CA 94025		No	No	Yes	No
1245624	James Healy	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025		No	No	Yes	No
1294340	Alain Azan	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025		No	No	Yes	No
1312272	Sofinnova Venture Affiliates Vi Lp	2800 Sand Hill Road, Suite 150 Menlo Park CA 94025		No	No	Yes	No
1362314	Eric Buatois	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025		No	No	Yes	No
1397188	Sofinnova Management Vi, L.l.c.	2800 Sand Hill Road, Suite 150 Menlo Park CA 94025		No	No	Yes	No
1397189	Sofinnova Venture Partners Vi Gmbh & Co. Kg	2800 Sand Hill Road, Suite 150 Menlo Park CA 94025		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-07-15	322,809	$6.03	1,025,364	No	4	P	Direct
Common Stock	Acquisiton	2013-07-15	63,957	$6.03	203,152	No	4	P	Direct
Common Stock	Acquisiton	2013-07-15	4,400	$6.03	13,976	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

Represents shares purchased in a private investment in Issuer's public equity transaction, the funding of which was conditioned on the closing of the merger of Ocera Subsidiary, Inc. (f/k/a Ocera Therapeutics, Inc.) with a wholly owned subsidiary of Ocera Therapeutics, Inc. (f/k/a Tranzyme, Inc.), in which transaction Ocera Subsidiary, Inc. was the surviving corporation.